ArticleChina CDC weekly2023
Confronting COVID-19 and Prioritizing Aging Population.
Article in China CDC weekly, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Pharmacokinetics and Safety of Single and Multiple Doses of Molnupiravir in Healthy Male Chinese Adults: An Open-Label, Fixed Sequence, Phase 1 Study.Clinical and translational science · 2026Article
- Adapting health, economic and social policies to address population aging in China.Nature aging · 2025Review
- Viral sepsis-induced mortality of older patients infected by the Omicron subvariant BA.5 of SARS-CoV-2: a retrospective study.BMC infectious diseases · 2025Article
- Microbial profile and antimicrobial resistance patterns of ocular infection pre/during and post the COVID-19 pandemic.Frontiers in medicine · 2025Article
- High Prevalence of Respiratory Co-Infections and Risk Factors in COVID-19 Patients at Hospital Admission During an Epidemic Peak in China.Infection and drug resistance · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the past three years, China has implemented rapid, vigorous, and coordinated control measures to limit the spread of coronavirus disease 2019 (COVID-19) effectively. These measures include active containment, graded management, rational resource allocation, rapid contact tracing and disposal, and targeted vaccination of key populations. These efforts have contributed to the prompt and effective control of outbreaks, protecting the health and well-being of older adults. This review provides a comprehensive summary of the changes in China's COVID-19 prevention and control experiences and other public health measures since the outbreak of the pandemic, and assesses their impact on older adults. It may serve as a valuable reference for future epidemic prevention and control efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.